PreAnalytiX, a joint venture between QIAGEN and BD, brings new solutions for smooth biopsy to market

^ VENLO, Niederlande and HOMBRECHTIKON, Switzerland, September 25, 2024 (GLOBE NEWSWIRE)

— PreAnalytiX GmbH, a joint venture of QIAGEN NV (NYSE: QGEN; Frankfurt,

Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), which

The latest marketing information for PAXgene(®) Urine Liquid Biopsy Set is available

gegeb. It is possible to analyze cell-free DNA (cell-free DNA,

cfDNA) from Urin with a range of molecular testing technologies, individually

qPCR, more digital PCR and Next-Generation Sequencing (NGS). Vertrieben was des

new set from QIAGEN.

The PAXgene Urine Liquid Biopsy Set contains herausforderung, cfDNA in Urin

Make sure you can operate your machine while processing a conservation solution.

User-friendly kit for urine and cfDNA stabilization is dabei

These are the first, verified, standardized and full-fledged standard

präanalytical workflow beetet, to use the cfDNA in Urin für

Research analyzes can help you shape your life.

cfDNA from urine offers great potential for research and future research

Clinical applications dar. See the reports and analysis of cfDNA-

Fragments, the natural genetic changes and mutations, die

The best immunity to methylation status is that of the Generierung Genomisscher Data, die

in Blutproben nicht zu finden since. The analysis of urinalysis is a piece of cake

a re-examination is the cfDNA after examining the results

An irrefuhrende genomic DNA freigesetzt can be.

Self-free DNA, which is isolated from urine, is non-invasive

Probenentnahme for the Flussigbiopsy, if jedoch a sorgfältige

Handhabung der Probe ergorderlich ist”, says Dr. Ellen Heitzer, Professorin an der

Medical University Graz in Austria. ?Das PAXgene urine fluid biopsy

Set up a standard urine test in clinical practice

an effort to get started ist. It is with different nightly analyses

compatible, with Hotspot, Genpanel and genome analyses, everything is possible

Consideration for additional information and information.”

?Many people, with the innovative PAXgene urine fluid biopsy kit,

Urgently use the market and have a problem with your urine flow, stabilization,

-transport and -bearing will operate, which are fully operational

Workflow for the integration of cfDNA-based tests that are integrated,” says

Dr. Uwe Oelmueller, Co-Chair of the PreAnalytiX Management Committee and

Leader of MDx Development Sample Technologies at QIAGEN. ?Fluid Biopsies

has enormous potential, there are major implications for the large number

Arbeitsalauf ab. It is the stabilization of the analysis profile in Proben

separated, a sicherzustellen, that is the Testergebnisse-zuverlässig and

be reproducible.”

The PAXgene Urine Liquid Biopsy Set is a great addition

Consider the quality, standardization and benefits of

Forscherinnen and Forscher are doing urine research. It’s a bit

Closed configuration kit for urine collection and cfDNA stabilization

Provide a choice of options for the probe’s sand and bearing. Es

can integrate the best workflows and is equipped with the right functionality

Compatible with testing products from QIAGEN. Entwickelt nach dem neuesten

European CEN/TS Standard for the präanalytical Handhabung von Urin zur

Isolation of free DNA can be optimized and standardized

Labor blauf. The Bezeichnung CEN/TS looks technical

Specifications introduced by the European Committee for Standards (CEN)

Where.

The urinary flute biopsy offers enormous possibilities, research and

If you want to help, you must accept a minimum rating, which is Wirkung

von Therapien zu überwachen und therapeutic Ziele zu identifizieren, indem

sie de ergebnisse der Blutplasma-Analyse erg en een umfassenderes

Common sense is possible. I think it’s a blood problem

all technical solutions for the energy sector, storage, transport

and Verarbeitung von Urinproben – a Lücke, the PAXgene Urine Liquid

Biopsy set to be performed now.

The new PAXgene Urine Liquid Biopsy Set replaces other QIAGEN marketed

Flüssigbiopsy- Lösungen, die alle Artsen von Analyten (zirkulierende zellfreie

Nukleinsäuren, Tumorzellen, Exosomes) see most molecules

Nachweistechnologie (NGS, qPCR, digital PCR) abdecken, um Forscher and Ärzte

in the lower zu verstzen, das Potenzial von Flüssigbiops in den

varied applications are fully available.

More about the PAXgene Urine Fluid Biopsy Kit can be found here:

https://www.qiagen.com/de-us/product-categories/discovery-and-translational-

research/sample collection-stabilization/dna.

About PreAnalytiX GmbH

PreAnalytiX was developed in 1999 by QIAGEN and BD, an integrated system for

Entnahme, Stabilisierung und Aufreinigung von Nukleinsäuren (DNA and RNA) for

Molecular diagnostics of the development, recovery and markets.

Additional information about PreAnalytiX and the PAXgene Urine Fluid Biopsy Kit

can be found at https://www.preanalytix.com.

About QIAGEN

QIAGEN NV, a Dutch holding company, is the world leader

An offer of comprehensive solutions for successful molecular recognition

from biological Testing. QIAGEN’s research technology has failed

Aufreinigung und Verarbeitung von DNS, RNS und Proteinen aus Blut, Gewebe und

other Substances. Testing technology can investigate and use these biomolecules

zur Analysis. Bioinformatic solutions and Wissensdatenbanken help

Interpretation of Daten zur Gewinnung more relevant and practically useful

Recognition. Automation solutions integrate these issues and

cost-effective molecular testing workflows. QIAGEN proposes more solutions

if 500,000 can be obtained from the Molecular Diagnosis (Gesundheitsfürsorge)

and Life Sciences (academical research, pharmacological F&E and industrial

Anwendungen, hauptsächlich Forensik) voor Verfügung. From June 30, 2024

civilized QIAGEN weltweit more than 5,900 employees in over 35 positions.

For more information about QIAGEN, visit http://www.qiagen.com.

About BD

BD is one of the major international medical technology companies, das

in itself the Fortschritt für die Welt der Gesundheit(TM) durch Verbesserungen in den

Treat the medical diagnosis, the diagnosis in the treatment

and Pflege von Patients zum Ziel gesetzt hat. Das Unternehmen unterstützt die

Medical Fachkräfte at your tagglichen Arbeit – with innovative people

Technologies, services and concepts that help the organization of the world

Patients can make the clinical diagnosis. BD and blessing

more than 70,000 workers and workers who live in large numbers

Commitment to care, treatment management to optimize, clinical procedure

reliable and efficient work, labor costs in the low price range,

Diseases are faster and more likely to be diagnosed and diagnosed

New diagnostic and treatment methods cannot be performed. BD ist

in fast all Ländern der Erde verteten and unterhält Partnerschaften mit

international organizations, one of the most pressing reforms in the world

Health care for people in the world is important. Dare to die

enge Zusammenarbeit with signals Kunden trägt BD dazu bei, bessere Clinic

The costs will be reduced, the efficiency in the clinic and labor will be reduced

erhöhen, patient and social security are improved in any case

zur Gesundheitsversorgung auszuweiten. More information about BD information

Visit bd.com or contact us via LinkedIn

http://www.linkedin.com/company/bd1/ (http://www.linkedin.com/company/bd1/u) and

X (Twitter) @BDandCo (https://twitter.com/BDandCo).

Forward-looking statement

One of the entries in the press release can be played in the Sin of Section 27A

the US Securities Act (US-Wertpapergesetz) from 1933 in ergänzter Fassung and

Section 21E of the US Securities Exchange Act (US-Börsengesetz) of 1934 in

ergänzter Fassung als zukunftsgerichtte Aussagen (?forward-looking statements”)

gilts. Soweit in dieser Notification zukunftsgerichttete Aussagen über QIAGENs

Products that are part of the response to the COVID-19 pandemic

Product, the Zeitplan für Marktinführungen und Entwicklungen, regulische

Genehmigungen, Financing und operative Prognosen, Wachstum, Expansionen,

Kollaborationen, Märkte, Strategie or operative Ergebnisse were authorized,

the only thing that hasn’t happened is that it’s very important for the

Cleaning Nettoumsatz and the cleansing waste Your action,

protection dies on the basis of time Erwartungen and Annahmen, which mit

Problems may occur and risks may be taken. These are calculated under

other: Risks in Zusammenhang with Wachstumsmanagement and internationally

Geschäftsaktivitäten (einschließlich Auswirkungen von Währungsschwankungen en

of the regulatory aspects of logistics processes); Schwankungen der

Betriebsergebnisse und je Verteilung auf unsere Kundengruppen; die Entwicklung

der Märkte für oursere Produkte and Kunden in der Akademischen Research, Pharma,

Extensive testing and molecular diagnosis; Changes below

Beziehungen zu Kunden, Lieferanten and strategic partners, das

Wettbewerbsumfeld, faster or unerwarteter technological walk,

Changes in the Nachfrage nach QIAGEN-Produkten (einschließlich overall

Wirtschaftlicher Entwicklungen, Höhe und Verfügbarkeit der Budgets unserer

Kunden und sonstiger Faktoren), de Möglichkeit, de regulische Zulassung

for our products that are there, difficulties with the application of QIAGENs

Products and integrated solutions and the repair-solcher products, which

The quality of the products, new products, products and the like

of the products of the law claimer are planning to use the law claim

shields, market acquisition new products and integration requests

Geschäfte und Technology; Maßnahmen von Regierungen; global or regional

economic economics; legal or transport clause Verzögerungen,

Natural disasters, political criticism or criticism in the policy of the public

Provide reassurance and an end to the COVID-19 pandemic and

– 3 – I look at the product and other products and other

Aspekte unseres Geschäfts, or sonstige Ereignisse höherer Gewalt; anyway dies

Effortless, that’s what’s worth it in life with youth or

Anstehenden Acquisitionen, not wie erwartet eintritt; and other factors,

angesprochen unter ?Risikofaktoren” in current Annual Report Form 20-F.

Further information can be found in News from QIAGEN outside the USA

Securities and Exchange Commission (US-Börsenaufsichtsbehörde) eingereicht hat.

Source: QIAGEN NV

Category: Corporate

Contact QIAGEN:

Investor Relations Public Relations

John Gilardi +49 2103 29 11711 Thomas Theuringer +49 2103 29 11826

Domenica Martorana +49 2103 29 11244 Lisa Specht +49 2103 29 14181

Email address: Email address: [email protected]

[email protected] (mailto:[email protected]

(mailto:[email protected] )

m)°